These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 26453388

  • 1. Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
    Solla P, Cannas A, Marrosu MG, Marrosu F.
    Parkinsonism Relat Disord; 2015 Nov; 21(11):1383-4. PubMed ID: 26453388
    [No Abstract] [Full Text] [Related]

  • 2. Burning mouth syndrome in Parkinson's disease: dopamine as cure or cause?
    Coon EA, Laughlin RS.
    J Headache Pain; 2012 Apr; 13(3):255-7. PubMed ID: 22322657
    [Abstract] [Full Text] [Related]

  • 3. Successful treatment of dopamine dysregulation syndrome with valproic acid.
    Epstein J, Madiedo CJ, Lai L, Hayes MT.
    J Neuropsychiatry Clin Neurosci; 2014 Apr; 26(3):E3. PubMed ID: 25093777
    [No Abstract] [Full Text] [Related]

  • 4. Levodopa-carbidopa intestinal gel is an option in Parkinson's disease with hyponatremia induced by dopamine agonists.
    Picillo M, Canoro V, Cicarelli G, Erro R, Barone P.
    Neurol Sci; 2020 Nov; 41(11):3361-3363. PubMed ID: 32506356
    [No Abstract] [Full Text] [Related]

  • 5. Dopamine agonist withdrawal syndrome (DAWS) symptoms in Parkinson's disease patients treated with levodopa-carbidopa intestinal gel infusion.
    Solla P, Fasano A, Cannas A, Mulas CS, Marrosu MG, Lang AE, Marrosu F.
    Parkinsonism Relat Disord; 2015 Aug; 21(8):968-71. PubMed ID: 26071817
    [Abstract] [Full Text] [Related]

  • 6. Dopamine agonist therapy for Parkinson disease and pathological gambling.
    Imamura A, Uitti RJ, Wszolek ZK.
    Parkinsonism Relat Disord; 2006 Dec; 12(8):506-8. PubMed ID: 16723269
    [Abstract] [Full Text] [Related]

  • 7. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [Abstract] [Full Text] [Related]

  • 8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [Abstract] [Full Text] [Related]

  • 9. Guillain-Barre/CIDP-like neuropathy in two parkinsonian patients following intestinal levodopa/carbidopa treatment.
    Galazky I, Schoof J, Stallforth S, Kupsch A, Heinze HJ, Kluge C.
    Parkinsonism Relat Disord; 2014 Jan; 20(1):125-7. PubMed ID: 24044946
    [No Abstract] [Full Text] [Related]

  • 10. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.
    Joseph CL, Siple J, McWhorter K, Camicioli R.
    J Am Geriatr Soc; 1995 Jan; 43(1):47-50. PubMed ID: 7806739
    [No Abstract] [Full Text] [Related]

  • 11. Biphasic Levodopa-Induced Freezing of Gait in Parkinson's Disease.
    Nonnekes J, Bloem BR.
    J Parkinsons Dis; 2020 Jan; 10(3):1245-1248. PubMed ID: 32417798
    [Abstract] [Full Text] [Related]

  • 12. [Application of levodopa/carbidopa intestinal gel in advanced Parkinson's disease].
    Toth A, Nagy H, Wacha J, Bereczki D, Takáts A.
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):191-6. PubMed ID: 26727723
    [Abstract] [Full Text] [Related]

  • 13. [Treatment of Parkinson's syndrome with a combination of levodopa and carbidopa].
    Lombardo L, De la Garza R.
    Arch Invest Med (Mex); 1977 Dec; 8(2):123-8. PubMed ID: 907417
    [Abstract] [Full Text] [Related]

  • 14. The D1/D5 Dopamine Partial Agonist PF-06412562 in Advanced-Stage Parkinson's Disease: A Feasibility Study.
    Huang X, Lewis MM, Van Scoy LJ, De Jesus S, Eslinger PJ, Arnold AC, Miller AJ, Fernandez-Mendoza J, Snyder B, Harrington W, Kong L, Wang X, Sun D, Delnomdedieu M, Duvvuri S, Mahoney SE, Gray DL, Mailman RB.
    J Parkinsons Dis; 2020 Dec; 10(4):1515-1527. PubMed ID: 32986682
    [Abstract] [Full Text] [Related]

  • 15. Parkinson's disease: making the diagnosis, selecting drug therapies.
    Scharre DW, Mahler ME.
    Geriatrics; 1994 Oct; 49(10):14-6, 20-3. PubMed ID: 7926845
    [Abstract] [Full Text] [Related]

  • 16. Reply to letter: Dopamine dysregulation syndrome in Parkinson's disease patients on levodopa-carbidopa intestinal gel.
    Marano M, Salomone G, di Biase L, Di Lazzaro V, Melgari JM.
    Parkinsonism Relat Disord; 2016 Apr; 25():114-5. PubMed ID: 26698016
    [No Abstract] [Full Text] [Related]

  • 17. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists.
    Horvath J, Fross RD, Kleiner-Fisman G, Lerch R, Stalder H, Liaudat S, Raskoff WJ, Flachsbart KD, Rakowski H, Pache JC, Burkhard PR, Lang AE.
    Mov Disord; 2004 Jun; 19(6):656-62. PubMed ID: 15197703
    [Abstract] [Full Text] [Related]

  • 18. Pharmacotherapy: problems and practices.
    Muenter MD.
    Clin Neuropharmacol; 1986 Jun; 9 Suppl 1():S23-36. PubMed ID: 3708606
    [Abstract] [Full Text] [Related]

  • 19. Dopamine dysregulation syndrome and punding in levodopa-carbidopa intestinal gel (LCIG) infusion: A serious but preventable complication.
    Salomone G, Marano M, di Biase L, Melgari JM, Di Lazzaro V.
    Parkinsonism Relat Disord; 2015 Sep; 21(9):1124-5. PubMed ID: 26242552
    [No Abstract] [Full Text] [Related]

  • 20. Dopamine dysregulation syndrome and psychosis in 24-h intestinal levodopa infusion for Parkinson's disease.
    Solla P, Cannas A, Meloni M, Marrosu F.
    Parkinsonism Relat Disord; 2016 Oct; 31():144-145. PubMed ID: 27423923
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.